Organization (Industry)
Aerin Medical Inc. (United States)
ClinicalTrials.gov lists Aerin Medical Inc. (United States) as lead sponsor of 15 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Aerin Medical Inc. (United States): 15 lead-sponsored trials and 1 legal-entity registration.
Disease areas (5)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Airway Obstruction | 11 |
| Nasal Obstruction | 11 |
| Respiratory Insufficiency | 11 |
| Common Cold | 1 |
| Rhinitis, Allergic | 1 |
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 1 |
| 2021 | 1 |
| 2020 | 6 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 1 |
| 2013 | 1 |
Recruitment duration, a model prediction: none of the 15 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 60% hit target (n=10) | 27% on time (n=11) |
Journals published in (16)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| International forum of allergy & rhinology | 6 |
| American journal of rhinology & allergy | 3 |
| OTO open | 2 |
| The Journal of allergy and clinical immunology | 2 |
| Advanced drug delivery reviews | 1 |
Showing 5 of 16 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 60 | 22 | 2025-11-18 |
Financing and grant events (3)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2024-12-13 | Private placement | 32,477,189 | Form d |
| 2022-04-28 | Private placement | 34,880,478 | Form d |
| 2020-08-04 | Private placement | 49,749,882 | Form d |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 2 |
FDA recalls (1)
| Product | Classification | Initiated |
|---|---|---|
| Aerin Medical VivAer Stylus, REF CAT1785 (individual stylus), and REF CAT500 (5-pack), sterile. | Class II | 2024-11-12 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| AERIN MEDICAL INC. | Mountain View, US | FDA |
Latest dated events (82)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-18 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-09-22 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-07-29 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-07-29 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 82 events.
Biomarker capability evidence (6)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| SSB | Trial sponsor | Named in trial inclusion criteria |
| NADK | Trial sponsor | Named in trial exclusion criteria |
| PNN | Trial sponsor | Named in trial exclusion criteria |
| NADK | Trial sponsor | Mentioned in trial text |
| PNN | Trial sponsor | Mentioned in trial text |
Showing 5 of 6 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, fda warning letters, fda untitled letters, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.